Bausch Health Companies intends to spin off Bausch + Lomb into a publicly traded entity separate from the remainder of the company, according to a press release.
Bausch + Lomb will be an eye health company, while a diversified Bausch Health will focus on gastroenterology, aesthetics/dermatology, neurology and international pharmaceuticals.
The company did not announce a specific time frame for the spinoff, citing the need for certain conditions and approvals. The reorganization of reporting segments is expected to be announced beginning in the first quarter of 2021.
“We are committed to